IL33 and asthma: Tozorakimab (anti-IL-33) is a monoclonal antibody studied in phase IIa clinical trial (FRONTIER-3) that is administered subcutaneously at a dose of 600 mg every 4 weeks, with potential benefits for early-onset eosinophilic (>300/μL) moderate-to-severe asthma [59].